Featured Research

from universities, journals, and other organizations

Post-transplant drug may also help patients with common genetic kidney disease

Date:
May 20, 2010
Source:
American Society of Nephrology
Summary:
The immunosuppressive drug sirolimus considerably improves the kidney health of patients with autosomal dominant polycystic kidney disease (ADPKD), according to a new study. The results suggest that this agent may be a promising treatment option for patients with ADPKD -- the most common genetic kidney disease and a major cause of kidney failure.

The immunosuppressive drug sirolimus considerably improves the kidney health of patients with autosomal dominant polycystic kidney disease (ADPKD), according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that this agent may be a promising treatment option for patients with ADPKD -- the most common genetic kidney disease and a major cause of kidney failure.

Related Articles


ADPKD causes cysts to grow within the kidney, affecting nearly 600,000 Americans and more than 10 million people worldwide. With no effective treatment, the disease often leads to enlarged kidneys and eventually kidney failure.

Research reveals that certain signals within cells may contribute to cyst growth in patients with ADPKD. These signals are part of what is known as the mammalian target of rapamycin (mTOR) pathway that controls cell growth and division. Giuseppe Remuzzi, MD, FRCP (Mario Negri Institute for Pharmacological Research, Bergamo, Italy) and his colleagues investigated, in a small pilot study, whether blocking this pathway with the mTOR inhibitor sirolimus (originally called rapamycin) might be an effective treatment strategy against ADPKD. (Sirolimus also acts as an immunosuppressant and is currently used to prevent rejection of kidney transplants.) Their clinical trial, called SIrolimus Treatment in Patients with Autosomal Dominant Polycystic Kidney Disease: RENAl Efficacy and Safety (SIRENA), examined how six months of treatment with sirolimus or conventional therapy affected different measures of kidney volume in 21 patients with ADPKD who had normal or slightly impaired kidney function.

Six of the 21 patients withdrew from the trial prematurely for various reasons. Data from the remaining patients demonstrated that sirolimus had a beneficial effect on the kidneys. Sirolimus therapy halted the growth of kidney cysts and increased the volume of healthy essential kidney structures, with an overall trend to slow the increase of total kidney volume. The investigators suspect that sirolimus may allow healthy kidney tissue to expand by relieving it from the compressing effects of surrounding cysts.

None of the patients in this trial developed serious side effects from receiving sirolimus. "This is the first randomized clinical study with mTOR inhibitor in ADPKD patients whose results have become available, and the findings provide the rationale for additional clinical trials aimed to assess whether chronic sirolimus therapy may improve clinical outcomes of ADPKD patients in the long run," said Dr. Remuzzi.

Study co-authors include Norberto Perico, MD, Luca Antiga, PhD, Anna Caroli, Nadia Rubis, Olimpia Diadei, Giulia Gherardi, Silvia Prandini, Andrea Panozo, MD, Rodolfo Flores Bravo, MD, Sergio Carminati, Felipe Rodriguez De Leon, MD, Flavio Gaspari, Monica Cortinovis, Nicola Motterlini, Bogdan Ene-Iordache (Mario Negri Institute for Pharmacological Research, in Bergamo, Italy); Piero Ruggenenti, MD (Mario Negri Institute for Pharmacological Research and Azienda Ospedaliera Ospedali Riuniti Bergamo); Giorgio Fasolini, MD, Mariateresa Cafaro, MD, Patrizia Ondei, MD (Azienda Ospedaliera Ospedali Riuniti Bergamo); and Andrea Remuzzi (Mario Negri Institute for Pharmacological Research and the University of Bergamo).

In reviewing the results of Dr. Remuzzi's study in an accompanying editorial, Robert Schrier, MD (University of Colorado Denver) stated that they give hope for the treatment of patients with ADPKD. He noted, however, that six months of sirolimus treatment was associated with mildly abnormal liver function tests, as well as increased cholesterol, decreased red blood cells, and increased protein excretion in the urine. "This is potentially bothersome regarding possible lifelong therapy for ADPKD," he wrote. "Thus, results of larger and longer follow-up studies in ADPKD patients with mTOR inhibitors will be very important."


Story Source:

The above story is based on materials provided by American Society of Nephrology. Note: Materials may be edited for content and length.


Journal Reference:

  1. N. Perico, L. Antiga, A. Caroli, P. Ruggenenti, G. Fasolini, M. Cafaro, P. Ondei, N. Rubis, O. Diadei, G. Gherardi, S. Prandini, A. Panozo, R. F. Bravo, S. Carminati, F. R. D. Leon, F. Gaspari, M. Cortinovis, N. Motterlini, B. Ene-Iordache, A. Remuzzi, G. Remuzzi. Sirolimus Therapy to Halt the Progression of ADPKD. Journal of the American Society of Nephrology, 2010; DOI: 10.1681/ASN.2009121302

Cite This Page:

American Society of Nephrology. "Post-transplant drug may also help patients with common genetic kidney disease." ScienceDaily. ScienceDaily, 20 May 2010. <www.sciencedaily.com/releases/2010/05/100513172856.htm>.
American Society of Nephrology. (2010, May 20). Post-transplant drug may also help patients with common genetic kidney disease. ScienceDaily. Retrieved November 24, 2014 from www.sciencedaily.com/releases/2010/05/100513172856.htm
American Society of Nephrology. "Post-transplant drug may also help patients with common genetic kidney disease." ScienceDaily. www.sciencedaily.com/releases/2010/05/100513172856.htm (accessed November 24, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, November 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

AFP (Nov. 23, 2014) The arable district of Kenema in Sierra Leone -- at the centre of the Ebola outbreak in May -- has been under quarantine for three months as the cocoa harvest comes in. Duration: 01:32 Video provided by AFP
Powered by NewsLook.com
Don't Fall For Flu Shot Myths

Don't Fall For Flu Shot Myths

Newsy (Nov. 23, 2014) Misconceptions abound when it comes to your annual flu shot. Medical experts say most people older than 6 months should get the shot. Video provided by Newsy
Powered by NewsLook.com
WFP: Ebola Risks Heightened Among Women Throughout Africa

WFP: Ebola Risks Heightened Among Women Throughout Africa

AFP (Nov. 21, 2014) Having children has always been a frightening prospect in Sierra Leone, the world's most dangerous place to give birth, but Ebola has presented an alarming new threat for expectant mothers. Duration: 00:37 Video provided by AFP
Powered by NewsLook.com
Could Your Genes Be The Reason You're Single?

Could Your Genes Be The Reason You're Single?

Newsy (Nov. 21, 2014) Researchers in Beijing discovered a gene called 5-HTA1, and carriers are reportedly 20 percent more likely to be single. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins